Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer

B Vaidya, V Parvathaneni, NS Kulkarni… - International journal of …, 2019 - Elsevier
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …
被引用次数：109 相关文章

Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer

B Vaidya, V Parvathaneni… - International …, 2019 - pubmed.ncbi.nlm.nih.gov
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.

B Vaidya, V Parvathaneni, NS Kulkarni… - … Journal of Biological …, 2018 - europepmc.org
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer

B Vaidya, V Parvathaneni… - International …, 2019 - researchworks.laverne.edu
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

[引用][C] Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer

B Vaidya, V Parvathaneni… - International …, 2019 - laverne-researchportal.esploro …
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer

B Vaidya, V Parvathaneni… - International …, 2019 - researchworks.laverne.edu
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer

B Vaidya, V Parvathaneni… - International …, 2019 - laverne-researchportal.esploro …
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

[引用][C] Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer

B Vaidya, V Parvathaneni, NS Kulkarni, SK Shukla… - 2019